Sanofi CSO David-Alexandre Gros On The Next Wave Of Growth In Emerging Markets: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
During a visit to Shanghai, Sanofi’s chief strategy officer sits down to talk about the company’s playbook for emerging markets, which focuses on both the BRIC countries and up-and-coming markets like Vietnam, Colombia and Nigeria.
You may also be interested in...
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
South of the Border: Sanofi’s Tailored Approach To Emerging Markets
Sanofi’s recent acquisition of Medley, Brazil’s leading generics manufacturer, reflects its strategy of going local — and generic — in emerging markets.
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.